Phenotype of the JAK2V617F KI mouse models used in Lamrani et al

PhenotypeInducible JAK2V617F (SCLCreERt)Constitutive JAK2V617F (vavCre)Suggested cause
Early (13 days)Late (60 days)
Reduced in vitro thrombosis √ — √ vWF proteolysis 
Reduced large vWF multimers √ — √ vWF proteolysis 
Platelet hypoactivity √ — √ Unclear 
Prolonged bleeding √ — √ vWF proteolysis 
Reduced platelet GPVI expression — √ √ Myelofibrosis 
Vasodilation — √ √ Adaptation to increased blood viscosity 
Clot lysis — √ √ Activation of proteases 
Rapid in vivo formation of unstable thrombi — √ √ Contribution JAK2V617F Erythrocytes/ leukocytes, thrombin generation 
PhenotypeInducible JAK2V617F (SCLCreERt)Constitutive JAK2V617F (vavCre)Suggested cause
Early (13 days)Late (60 days)
Reduced in vitro thrombosis √ — √ vWF proteolysis 
Reduced large vWF multimers √ — √ vWF proteolysis 
Platelet hypoactivity √ — √ Unclear 
Prolonged bleeding √ — √ vWF proteolysis 
Reduced platelet GPVI expression — √ √ Myelofibrosis 
Vasodilation — √ √ Adaptation to increased blood viscosity 
Clot lysis — √ √ Activation of proteases 
Rapid in vivo formation of unstable thrombi — √ √ Contribution JAK2V617F Erythrocytes/ leukocytes, thrombin generation 

The hematopoietic-specific JAK2V617F mouse models of PV/MF were generated by transplantation of bone marrow from inducible (SCLCreERt) and constitutive (VavCre) JAK2V617F knock-in mice. For the inducible mouse model, both the early (13 days after induction of JAK2V617F expression) and late (60 days after induction of JAK2V617F expression) phenotypes are indicated. The underlying cause of the observed phenotype, as suggested by Lamrani et al, is also included. √, phenotype observed.

Close Modal

or Create an Account

Close Modal
Close Modal